Guangzhou, China

Fengyan Yu

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Children's Medical Center Corporation. Active years: 2021.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fengyan Yu: Innovator in Cancer Therapeutics

Introduction

Fengyan Yu is a prominent inventor based in Guangzhou, China. He has made significant contributions to the field of cancer therapeutics, particularly through his innovative research on microRNAs.

Latest Patents

Fengyan Yu holds a patent titled "Let-7 microRNA and mimetics thereof as therapeutics for cancer." This invention relates to methods for treating or preventing cancers by targeting cancer stem cells. The patent outlines a method of administering miRNAs that are reduced or lacking in cancer stem cells, specifically let-7 miRNAs. Additionally, it discusses alternative methods that involve administering miRNAs with increased expression levels in cancer stem cells. The invention also includes methods to enrich for a cancer stem cell population and identify miRNAs that contribute to the self-renewal capacity of these cells.

Career Highlights

Fengyan Yu is associated with the Children's Medical Center Corporation, where he continues to advance his research in cancer treatment. His work has the potential to significantly impact therapeutic strategies for cancer patients.

Collaborations

Fengyan Yu has collaborated with notable researchers, including Judy Lieberman and Erwei Song. These collaborations have further enriched his research and contributed to the development of innovative cancer therapies.

Conclusion

Fengyan Yu's work in the field of cancer therapeutics exemplifies the importance of innovation in medical research. His contributions through patents and collaborations highlight his commitment to improving cancer treatment options.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…